Investment Analysts’ Weekly Ratings Changes for Jazz Pharmaceuticals (JAZZ)

Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

• 1/12/2026 – Jazz Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Jazz Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $225.00 price target on the stock.
• 12/29/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $219.00 price target on the stock, up previously from $147.00.
• 12/8/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Jazz Pharmaceuticals had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $188.00 price target on the stock, up previously from $163.00.
• 11/24/2025 – Jazz Pharmaceuticals had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $188.00 price target on the stock, up previously from $163.00.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an “outperform” rating on the stock.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $230.00 to $247.00. They now have a “buy” rating on the stock.
• 11/17/2025 – Jazz Pharmaceuticals was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 11/17/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, Director Heather Ann Mcsharry sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director owned 20,449 shares of the company’s stock, valued at $3,635,423.22. The trade was a 14.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $182.06, for a total transaction of $968,377.14. Following the completion of the sale, the chief accounting officer owned 7,012 shares in the company, valued at $1,276,604.72. This represents a 43.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 123,791 shares of company stock valued at $21,991,850. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.